You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Biosense Webster
Clinical Evidence
Biosense Webster
Clinical Evidence
Biosense Webster, Inc. is committed to the dissemination of scientific evidence in peer-reviewed journals. We are proud of our track record of publishing cutting-edge clinical research that fuels the development of devices, which provide novel alternatives for the treatment of complex heart arrhythmias.
MEDIA
Biosense Webster, Inc. is committed to the dissemination of scientific evidence in peer-reviewed journals. We are proud of our track record of publishing cutting-edge clinical research that fuels the development of devices, which provide novel alternatives for the treatment of complex heart arrhythmias.
VISTAX Prospective, Multicenter, Nonrandomized Study
Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: The multicentre VISTAX trial. Duytschaever M, et al. Europace. 2021;23(3):362-369.
VISTAX demonstrated the reproducibility of an optimized VISITAG SURPOINT™ Module PVI ablation workflow in patients with drug refractory paroxysmal AF treated in 17 European sites. ~90% of patients were free of arrhythmia recurrence or repeat ablation at 12-month.
PRECEPT Prospective, Multicenter, Nonrandomized Study
Persistent atrial fibrillation ablation with contact force-sensing catheter: The prospective multicenter PRECEPT trial
Mansour M, et al. JACC Clin Electrophysiol. 2020;6(8):958-969.
PRECEPT evaluated safety/effectiveness of persistent atrial fibrillation ablation with the contact-force sensing THERMOCOOL SMARTTOUCH™ SF Catheter and CARTO VISITAG™ Module using a tailored PVI-only/PVI+ approach. 80% of patients experienced clinical success (ie, freedom from symptomatic recurrence) at 15 months.
ATTEST Prospective, Multicenter, Randomized Controlled Study
Catheter ablation or medical therapy to delay progression of atrial fibrillation: The randomized controlled atrial fibrillation progression trial (ATTEST) Kuck, K-H, et al. Europace. 2021;23(3):362-369.
ATTEST was the first randomized study demonstrating that early RF catheter ablation is superior to antiarrhythmic drug therapy in delaying AF progression. RF ablation patients were approximately 10x less likely to progress to persistent AF.
Standardization of AF Ablation Workflow With THERMOCOOL SMARTTOUCH© CATHETER and VISITAG SURPOINT™ Module
Meta-Analysis THEMOCOOL SMARTTOUCH® Catheter Ablation vs Other Technologies
